Atopic dermatitis (AD) is entering a new era. Once treated with a narrow range of topical steroids and systemic immunosuppressants, AD now has an expanding pipeline of biologics, small-molecule inhibitors, and innovative adjunct therapies that promise safer, more effective, and more personalized care.

This white paper explores the evolving therapeutic landscape of AD—including the science behind emerging agents, updated clinical trial data, and the challenges of trial design in this complex, heterogeneous disease. Whether you’re navigating new endpoints, designing trials for pediatric populations, or planning for biomarker-based stratification, this comprehensive resource offers strategic insights for sponsors at every stage.

Inside the white paper:

• Pathophysiology and clinical phenotypes of AD across the lifespan
• New treatment targets: IL-13, IL-31, TYK2, AhR, H4R, and more
• Approved and investigational small molecules and biologics
• Adjunctive therapies including probiotics and lipid-based treatments
• Challenges in trial design, from placebo effect to endpoint variability
• Future directions in precision dermatology and patient stratification

Learn more about our related services and resources:

TFS Dermatology